Cargando…

An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis

The presence and stage of liver fibrosis in patients with nonalcoholic steatohepatitis (NASH) is strongly associated with mortality. Thus, both preventing and reversing fibrosis are critically important approaches to prevent death or the need for liver transplantation from NASH. Recently, fibrosis i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ulmasov, Barbara, Noritake, Hidenao, Carmichael, Peter, Oshima, Kiyoko, Griggs, David W., Neuschwander‐Tetri, Brent A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357833/ https://www.ncbi.nlm.nih.gov/pubmed/30766962 http://dx.doi.org/10.1002/hep4.1298

Ejemplares similares

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
por: Sharpe, Martin C., et al.
Publicado: (2023)

Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice
por: Ulmasov, Barbara, et al.
Publicado: (2016)

Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
por: Mukherjee, Sandip, et al.
Publicado: (2021)

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
por: Clearfield, Elizabeth, et al.
Publicado: (2021)

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis
por: Sanyal, Arun, et al.
Publicado: (2023)

The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance
por: Gill, Ryan M., et al.
Publicado: (2023)

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
por: Griffett, Kristine, et al.
Publicado: (2015)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease
por: de Bari, Ornella, et al.
Publicado: (2012)

The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients with Nonalcoholic Steatohepatitis
por: Rangboo, Vajiheh, et al.
Publicado: (2016)

Physical stability of arginine-glycine-aspartic acid peptide coated on anodized implants after installation
por: Huh, Jung-Bo, et al.
Publicado: (2013)

Conjugates of Copper Alginate with Arginine-Glycine-Aspartic Acid (RGD) for Potential Use in Regenerative Medicine
por: Fraczyk, Justyna, et al.
Publicado: (2020)

Evaluation of the Biodistribution of Arginine, glycine, aspartic acid peptide-modified Nanoliposomes Containing Curcumin in Rats
por: Salehi Najafabadi, Parisa, et al.
Publicado: (2022)

Antilung cancer effect of ergosterol and cisplatin-loaded liposomes modified with cyclic arginine-glycine-aspartic acid and octa-arginine peptides
por: Wu, Meijia, et al.
Publicado: (2018)

The efficacy of aspartate aminotransferase-to-platelet ratio index for assessing hepatic fibrosis in childhood nonalcoholic steatohepatitis for medical practice
por: Kim, Earl, et al.
Publicado: (2013)

Cyclic arginine-glycine-aspartate attenuates acute lung injury in mice after intestinal ischemia/reperfusion
por: Matsuo, Shingo, et al.
Publicado: (2013)

Arginine–glycine–aspartate (RGD)-targeted positron-labeled dendritic polylysine nanoprobe for tumor PET imaging
por: Fang, Qi, et al.
Publicado: (2020)

Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr(-/-) Mice Reversible?
por: Lytle, Kelli A., et al.
Publicado: (2016)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy
por: QIN, LI, et al.
Publicado: (2014)

Thermal decomposition of the amino acids glycine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine and histidine
por: Weiss, Ingrid M., et al.
Publicado: (2018)

Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
por: Wang, Chen, et al.
Publicado: (2022)

Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple
por: Yuan, Liyun, et al.
Publicado: (2021)

Effects of arginine–glycine–aspartic acid peptide-conjugated quantum dots-induced photodynamic therapy on pancreatic carcinoma in vivo
por: Li, Ming-Ming, et al.
Publicado: (2017)

Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis
por: Chen, Hui, et al.
Publicado: (2022)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
por: Gay, Martha D., et al.
Publicado: (2022)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice
por: Wang, Xiaobo, et al.
Publicado: (2019)

Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis?
por: Jirapinyo, Pichamol, et al.
Publicado: (2019)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6lsst3n9pk2322aj10p1ce6a2t